京原

Beijing Jingyuan Biotechnology (Jingyuan Bio) is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of next-generation T-cell receptor engineered T-cell (TCR-T) therapies. The company focuses on addressing the challenges of treating solid tumors by leveraging its proprietary TCR-T 2.0 platform to identify high-affinity TCRs and optimize cell persistence and infiltration. Its lead candidate, JY-101, targets HPV16-positive malignancies such as cervical and head and neck cancers and is currently undergoing Phase 1 clinical evaluation. Jingyuan Bio aims to provide curative options for patients with advanced solid tumors through its robust pipeline of antigen-specific immune therapies. The company has attracted significant investment from leading venture capital firms, including IDG Capital and Sequoia China, to support its mission of advancing precision oncology.